Theratope® vaccine (STn-KLH)

Bibliography

• BORGES E, WIESMULLER K-H, JUNG G, WALDEN P: Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. Iinmunother. (1993) 36:215–222
   Google Scholar
• CORMIER JN, SALGALLER ML, PREVETTE T et al: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melen A. Cancer J. Sci. Am. (1997) 3(1):37–44.
   PubMed Web of Science ®Google Scholar
• KANTOR J, IRVINE K, ABRAMS S, KAUFMAN H, DIPIETRO J, SCHLOM J: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. j Natl. Cancer Inst. (1992) 84:1084–1091.
   PubMed Web of Science ®Google Scholar
• TSANG KY, ZAREMBA S, NIERODA CA, ZHU MZ, HAMILTON JM, SCHLOM J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccina-CEA vaccine. j Nati Cancer Inst. (1995) 87:982–990.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON PO, WONG GYC, ADLURI S et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. j CM]. Omni (1994) 12:1036–1044.
   PubMed Web of Science ®Google Scholar
• MACLEAN GD, REDDISH MA, KOGANTY RR et al: Immunization of breast cancer patients using a synthetic Sialyl-Tn glycoconjugate plus Detox TM adjuvant. Cancer Immune]. Iinmunother. (1993) 36:215–222.
   PubMed Web of Science ®Google Scholar
• •Initial Phase I clinical study with Theratope vaccine.
   Google Scholar
• LONGENECKER BM, REDDISH M, KOGANTY R, MACLEAN GD: Immuneresponses of mice and human breast cancer patients following immunization with synthetic Sialyl-Tn coryugatedto KLH plus Detox adjuvant. Ann. NY Acad. Sci. (1993) 690:276–291.
   PubMed Web of Science ®Google Scholar
• MACLEAN GD, REDDISH MA, LONGENECKER BM: Antibodies against mucin-associated Sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. j kmauriother. (1996) 19:59–68.
   Google Scholar
• •Documents antibody responses generated to Theratope® vaccine.
   Google Scholar
• MACLEAN GD, MILES DW, RUBENS RD, REDDISH MA, LONGENECKER BM: Enhancing the effect of Theratope® STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low dose intravenous cyclophosphamide. j Immunother. (1996) 19:309–316.
   PubMed Web of Science ®Google Scholar
• ••Shows positive effect of iv. cyclophosphamide on administration of Theratope® in a clinical trial.
   Google Scholar
• THOR A, OHUCHI N, SZPAK CA, JOHNSTON WW, SCHLOM J: Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. (1986) 46:3118–3124.
   PubMed Web of Science ®Google Scholar
• REDDISH MA, JACKSON L, KOGANTY RR, QIU D, HONG W LONGENECKER BM: Specificities of anti-Sialyl Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Clycoryugate J. (1997) 14:549–560.
   Google Scholar
• ITZKOWITZ SH, BLOOM EJ, KOKAW WA, MODIN G, HAKOMORI S-I, KIM YS: Sialosyl -Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer (1990) 66:1960–1989.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, TERAO T, KAWASHIMA Y: Serum Sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. CM]. Oricol (1992)10:95–101.
   PubMed Web of Science ®Google Scholar
• MILES DW, HAPPERFIELD LC, SMITH P et al.: Expression of Sialyl-Tn predicts the effect of adjuvant chemotherapy in node positive breast cancer. Br j Cancer (1994) 70:1272–1275.
   PubMed Web of Science ®Google Scholar
• MILES DW, LINEHAN J, SMITH P, FILIPE I: Expression of Sialyl-Tn in gastric cancer: correlation with known prognostic factors. Br. J. Cancer (1995) 71:1074–1076.
   PubMed Web of Science ®Google Scholar
• FUNG PYS, MADEJ M, KOGANTY RR, LONGENECKER BM: Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. (1990) 50:4308–4314.
   PubMed Web of Science ®Google Scholar
• •Preclinical trial of cyclophosphamide and glycoconjugate vaccine.
   Google Scholar
• SINGHAL A, FOHN M, HAKOMORI SI: Induction of alpha N-acetylgalactosamine-0-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res. (1991) 51:1406–1411.
   PubMed Web of Science ®Google Scholar
• ELGERT KD, FARRAR WL: Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T-lymphocytes and macrophages. (1978) 120:1345–1353.
   Google Scholar
• NORTH RJ, BURSUKER I: Generation and decay of the immune response to a progressive fibrosarcoma. I Exp. Med. (1984) 159:1295–1311.
   PubMed Web of Science ®Google Scholar
• YU A, WATTS H, JAFFE N, PARKMAN R: Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N Engl. Med. (1977) 297:121–127.
   PubMed Web of Science ®Google Scholar
• CATALONA WJ, RATILIFF TL, MCCOOL RE: Concanavalin A-activated suppressor cell activity in the peripheral blood lymphocytes of urology cancer patients. j Natl. Cancer Inst. (1980) 65:553–557.
   PubMed Web of Science ®Google Scholar
• BURSUKER I, NORTH RJ: Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T-cells from tumor-bearing donors. Cancer bronuriol Immurither. (1985) 19:215–218.
   Google Scholar
• FUNG PYS, LONGENECKER BM: Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. (1991) 51:1170–1176.
   PubMed Web of Science ®Google Scholar
• BERD D, MASTRANGELO MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Inv. (1988) 6:337–349.
   PubMed Web of Science ®Google Scholar
• MILES DW, TOWLSON KE, GRAHAM R et al.: A randomized Phase II study of Sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer (1996) 74:1292–1296.
   PubMed Web of Science ®Google Scholar
• •Randomised Phase II non-transplant study.
   Google Scholar
• BOWEN YACYSHYN MB, POPPEMA S, BERG A etal.: CD69+ and HLADr+ activation antigens on peripheral blood lymphocyte populations in metastatic beast and ovarian cancer patients: correlation with survival following active specific immunotherapy. bit. j Cancer (1995) 61:470–474.
   Google Scholar
• PICHLER WJ, WYSS-CORAY T: T-cells asantigen-presenting cells. Immuriol. Today (1994) 15:312–315.
   PubMedGoogle Scholar
• REDDISH MA, MACLEAN GD, POPPEMA S, BERG A, LONGENECKER BM: Pre-immunotherapy serum CA 27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of THERATOPE Sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer bronuriol kmauriother. (1996) 42:303–309.
   Google Scholar
• AGRAWAL B, KRANTZ MJ, REDDISH MA, LONGENECKER BM: Cancer-associated MUC1 mucin inhibit human T cell proliferation which is reversible by IL-2. Nature Med. (1998) 4:43–49.
   PubMed Web of Science ®Google Scholar
• •Documents that mucin can cause immune anergy.
   Google Scholar
• STOREK J AND WITHERSPOON RP: Immunological reconstitution after hematopoetic stem cell transplant. In: Clinical Bone Marrow and Blood Stem Cell Transplantation(Edition 2). Atkinson K (Ed.) Cambridge, UK (2000):111–146.
   Google Scholar
• SANDMAIER BM, OPARIN DV, HOLMBERG LA, REDDISH MA, MACLEAN GD, LONGENECKER BM: Evidence for a cellular immune response against Sialyl-Tn in breast and ovarian cancer patients following high dose chemotherapy, stem cell rescue and immunization with Theratope® vaccine STn-KLH cancer vaccine. j Immunother. (1999) 22:54–66.
   PubMed Web of Science ®Google Scholar
• •Shows immune responses generated by Theratope® when given after autologous transplant.
   Google Scholar
• HARDY CV, KIHLBERG J, ELOFSSON M, MAGNUSSON G, UNANUE ER: Glycopeptides bind MHC molecules and elicit specific T cell responses. j Immuriol (1993) 151:2419–2425.
   Google Scholar
• •Documents T-cell recognition of carbohydrate antigens.
   Google Scholar
• HARUM JS, ARSEQUELL G, LELLOCH AC etal.: Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. j Exp. Med. (1994) 180:734–744.
   Google Scholar
• •Documents T-cell recognition of carbohydrate antigens.
   Google Scholar
• DECK B, ELOFSSON M, KIHLBERG J, UNANUE ER: Specificity of glycopeptide-specific T cells. j. brununol. (1995) 155:1074–1078.
   Google Scholar
• JENSEN T, GALLI-STAMPINO L, MOURITSEN S et al.: T cell recognition of Tn-glycosylated peptide antigens. Eur. 1ran. (1996) 26:1324–1349.
   Google Scholar
• •Documents T-cell recognition of carbohydrate antigens.
   Google Scholar
• GALLI-STAMPINO L, MEINJOHANNS E, FRISCHE K et al.: T-cell recognition of tumor-associated carbohydrates: the nature of the gylcan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res. (1997) 57:3214–3222.
   PubMed Web of Science ®Google Scholar
• •Documents T-cell recognition of carbohydrate antigens.
   Google Scholar
• HOLMBERG LA, OPARIN DV, GOOLEY T et al.: Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® vaccine STn-KLH cancer vaccine. Bone Marrow Trawl. (2000) 25:1233-1241. Clinical experience with Theratope® given after autologous transplant.
   Google Scholar